Cubist Cidecin NDA For Mid-2002; Launch Will Need Up To 150 Reps, CEO Says
Executive Summary
Cubist's will file an NDA for its intravenous antibiotic Cidecin (daptomycin) in mid-2002, CEO Scott Rocklage told analysts during Bear Stearns' "virtual" healthcare conference Sept. 24.
You may also be interested in...
Cubist Cubicin Marketing To Highlight Single Daily Dose Of Antibiotic
Cubist's Cubicin (daptomycin) will be promoted for its single daily dosing compared to traditional antibiotics administered at least twice daily
Cubist Cubicin Marketing To Highlight Single Daily Dose Of Antibiotic
Cubist's Cubicin (daptomycin) will be promoted for its single daily dosing compared to traditional antibiotics administered at least twice daily
InterMune Oritavancin Marketing Will Quadruple Firm's Sales Force To 200
InterMune will add 150 sales representatives to its 48-person U.S. force over the next three years for launch of Lilly's glycopeptide antibiotic oritavancin.